Raloxifene bismethyl ether
CAS: 84541-38-8
Rif. 3D-FR27667
| 5mg | Fuori produzione | ||
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione | ||
| 50mg | Fuori produzione | ||
| 100mg | Fuori produzione |
Informazioni sul prodotto
- 6-Methoxy-2-(4-methoxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone[6-Methoxy-2-(4-methoxyphenyl)benzo[b] thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone
- [6-Methoxy-2-(4-methoxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone
Raloxifene bismethyl ether is a deformation product of raloxifene that is used to treat osteoporosis. It has been shown to increase bone mass and prevent the loss of bone density in postmenopausal women by regulating the activity of collagen, a protein that forms the matrix for bone cells. Recent clinical trials have shown that raloxifene bismethyl ether significantly increases bone mineral density and reduces fractures in postmenopausal women with low bone mass. The mechanism of action of this drug is not fully understood but it is thought to be due to its ability to inhibit the rate at which collagen breaks down, thereby increasing the amount of collagen present in the body. Raloxifene bismethyl ether also inhibits estrogen-induced proliferation of breast cancer cells and may reduce risk for endometrial cancer, although more research is needed.
